Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis : A real-life observational study
Copyright © 2023. Published by Elsevier B.V..
BACKGROUND: Pediatric forms of multiple sclerosis are more active than those in adults. Yet, the effectiveness of different therapeutic approaches is not well studied in this population. Our objective was to compare the effectiveness of the early use of high efficacy therapies (HETs) with the effectiveness of moderate efficacy therapies (METs) in children with MS.
METHODS: This observational study included patients diagnosed with pediatric MS, at 4 hospital centers in France, during a 10-year period. METs included: interferon β-1a, glatiramer acetate, dimethyl fumarate, teriflunomide; HETs included: fingolimod, natalizumab, ocrelizumab, alemtuzumab. The primary endpoint was the occurrence of a new relapse, the secondary endpoint was EDSS worsening.
RESULTS: Sixty-four patients were included in the analysis (80% women; mean age 15.5 years, 81% treated with MET) with a median follow-up of 22.5 months. At baseline, 52 patients were on MET (interferon β-1a, glatiramer acetate, dimethyl fumarate, teriflunomide) and 12 patients were on HET (natalizumab, ocrelizumab). The cumulative probability of being relapse-free at 6.5 years was 23.3% on MET, vs 90.9% on HET (p = 0.013). The cumulative probability of no EDSS worsening did not differ between the 2 groups.
CONCLUSION: Patients starting with METs had much higher clinical disease activity than those starting early with HETs. Rapid initiation of more aggressive treatment may allow better disease control; however, the data on EDSS worsening are not conclusive.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
|---|---|
| Enthalten in: |
Multiple sclerosis and related disorders - 79(2023) vom: 01. Nov., Seite 104942 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Moreau, Augustin [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.11.2023 Date Revised 16.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.msard.2023.104942 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361312040 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361312040 | ||
| 003 | DE-627 | ||
| 005 | 20231226084855.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.msard.2023.104942 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1204.xml |
| 035 | |a (DE-627)NLM361312040 | ||
| 035 | |a (NLM)37633034 | ||
| 035 | |a (PII)S2211-0348(23)00443-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Moreau, Augustin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis |b A real-life observational study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.11.2023 | ||
| 500 | |a Date Revised 16.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier B.V. | ||
| 520 | |a BACKGROUND: Pediatric forms of multiple sclerosis are more active than those in adults. Yet, the effectiveness of different therapeutic approaches is not well studied in this population. Our objective was to compare the effectiveness of the early use of high efficacy therapies (HETs) with the effectiveness of moderate efficacy therapies (METs) in children with MS | ||
| 520 | |a METHODS: This observational study included patients diagnosed with pediatric MS, at 4 hospital centers in France, during a 10-year period. METs included: interferon β-1a, glatiramer acetate, dimethyl fumarate, teriflunomide; HETs included: fingolimod, natalizumab, ocrelizumab, alemtuzumab. The primary endpoint was the occurrence of a new relapse, the secondary endpoint was EDSS worsening | ||
| 520 | |a RESULTS: Sixty-four patients were included in the analysis (80% women; mean age 15.5 years, 81% treated with MET) with a median follow-up of 22.5 months. At baseline, 52 patients were on MET (interferon β-1a, glatiramer acetate, dimethyl fumarate, teriflunomide) and 12 patients were on HET (natalizumab, ocrelizumab). The cumulative probability of being relapse-free at 6.5 years was 23.3% on MET, vs 90.9% on HET (p = 0.013). The cumulative probability of no EDSS worsening did not differ between the 2 groups | ||
| 520 | |a CONCLUSION: Patients starting with METs had much higher clinical disease activity than those starting early with HETs. Rapid initiation of more aggressive treatment may allow better disease control; however, the data on EDSS worsening are not conclusive | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Multiple sclerosis | |
| 650 | 4 | |a Observational study | |
| 650 | 4 | |a Pediatrics | |
| 650 | 4 | |a Survival analysis | |
| 650 | 4 | |a Therapeutics | |
| 650 | 4 | |a Treatment Outcome | |
| 650 | 7 | |a Dimethyl Fumarate |2 NLM | |
| 650 | 7 | |a FO2303MNI2 |2 NLM | |
| 650 | 7 | |a Fingolimod Hydrochloride |2 NLM | |
| 650 | 7 | |a G926EC510T |2 NLM | |
| 650 | 7 | |a Glatiramer Acetate |2 NLM | |
| 650 | 7 | |a 5M691HL4BO |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Interferon beta-1a |2 NLM | |
| 650 | 7 | |a XRO4566Q4R |2 NLM | |
| 650 | 7 | |a Natalizumab |2 NLM | |
| 650 | 7 | |a teriflunomide |2 NLM | |
| 650 | 7 | |a 1C058IKG3B |2 NLM | |
| 700 | 1 | |a Kolitsi, Ioanna |e verfasserin |4 aut | |
| 700 | 1 | |a Kremer, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Fleury, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Lanotte, Livia |e verfasserin |4 aut | |
| 700 | 1 | |a Sellal, François |e verfasserin |4 aut | |
| 700 | 1 | |a Gaultier, Claude |e verfasserin |4 aut | |
| 700 | 1 | |a Ahle, Guido |e verfasserin |4 aut | |
| 700 | 1 | |a Courtois, Sylvie |e verfasserin |4 aut | |
| 700 | 1 | |a Fickl, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Mostoufizadeh, Sohrab |e verfasserin |4 aut | |
| 700 | 1 | |a Dentel, Christel |e verfasserin |4 aut | |
| 700 | 1 | |a Collongues, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a de Seze, Jérôme |e verfasserin |4 aut | |
| 700 | 1 | |a Bigaut, Kévin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Multiple sclerosis and related disorders |d 2012 |g 79(2023) vom: 01. Nov., Seite 104942 |w (DE-627)NLM219118388 |x 2211-0356 |7 nnns |
| 773 | 1 | 8 | |g volume:79 |g year:2023 |g day:01 |g month:11 |g pages:104942 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.msard.2023.104942 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 79 |j 2023 |b 01 |c 11 |h 104942 | ||